KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Income from Continuing Operations data on record, last reported at 844600000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 7.97% year-over-year to 844600000.0; the TTM value through Dec 2025 reached 4504900000.0, up 2.09%, while the annual FY2025 figure was 4504900000.0, 2.09% up from the prior year.
  • Income from Continuing Operations reached 844600000.0 in Q4 2025 per REGN's latest filing, down from 1460000000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3098900000.0 in Q2 2021 and bottomed at 1507900000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 1080800000.0, with a median of 1007800000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 245.36% in 2021, then plummeted 72.5% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 1816600000.0 in 2021, then crashed by 183.01% to 1507900000.0 in 2022, then skyrocketed by 176.9% to 1159600000.0 in 2023, then decreased by 20.86% to 917700000.0 in 2024, then dropped by 7.97% to 844600000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 844600000.0 in Q4 2025, 1460000000.0 in Q3 2025, and 1391600000.0 in Q2 2025.